Series A1 · BiotechCaldera Therapeutics: Series A1Develops bispecific antibody CLD-423 for inflammatory bowel diseasePublished Oct 4, 2026By RoundOS Funding deskFunding historyJan 14, 2026Series A1 · This round$37.5MSourcesbusinesswire.com↗
AusperBioDevelops oligonucleotide therapeutics targeting chronic hepatitis B$120MSeries C · Aug 27, 2026
ProFound TherapeuticsUses AI and proteomics to discover drug targets and biomarkers for preeclampsia and eclampsia$35MStrategic · Aug 27, 2026
TransfyrPhysical AI platform capturing real-world lab science into machine-readable data$25MSeed · Aug 26, 2026
Airway TherapeuticsDevelops biologic therapies for respiratory and infectious diseases$50MSeries E2 · Aug 25, 2026